Pay in 4 interest-free payments of $6.34 Learn more
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26
Each batch undergoes third-party testing by certified labs to verify composition and quality
Chorionic gonadotropin: Adverse effects database
Back in 2018, most of its earnings came from generics, with only a small share driven by innovation. Between 2025 and 2027, the company expects to bring dozens of major breakthroughs to market from GLP-1 therapies for obesity and diabetes to next-generation oncology treatments. Source: *Opinions are my own To view or add a comment, sign in Big Pharma News: Pfizer is set to acquire Metsera in a deal worth up to $4.9B Why it matters: $47.50/share upfront + $22.50/share tied to milestones Lead candidate MET-097i (GLP-1 therapy) showed 11.3% weight loss in 12 weeks Pipeline includes monthly amylin-based injections + oral obesity drugs Puts Pfizer head-to-head with Lilly & Novo Nordisk in the obesity race This move highlights the booming obesity drug market and pharmas growing appetite for metabolic innovation
He followed up with and MRI and it showed nothing
M.et al (2001)
US$ 20.61
US$ 27.25
US$ 23.98
US$ 28.45
US$ 20.29
US$ 24.20
